Generalized Anxiety or Depression Measured by the Hamilton Anxiety Scale and the Melancholia Scale in Patients before and after Cardiac Surgery

1984 ◽  
Vol 17 (5-6) ◽  
pp. 253-263 ◽  
Author(s):  
P. Bech ◽  
H. Grosby ◽  
B. Husum ◽  
L. Rafaelsen
Keyword(s):  
Cardiac Surgery ◽  
Anxiety Scale ◽  
Generalized Anxiety ◽  
Before And After ◽  
Hamilton Anxiety Scale ◽  
Hamilton Anxiety

Treatment of Methadone Withdrawal with Cerebral Electrotherapy (Electrosleep)

1979 ◽  
Vol 134 (1) ◽  
pp. 111-113 ◽  
Author(s):  
Evaristo Gomez ◽  
Adib R. Mikhail
Keyword(s):  
Marked Reduction ◽  
Anxiety Scale ◽  
The Other ◽  
Control Group ◽  
Taylor Manifest Anxiety Scale ◽  
Before And After ◽  
Hamilton Anxiety Scale ◽  
Manifest Anxiety ◽  
Drug Free ◽  
Hamilton Anxiety

SummaryThe use of cerebral electrotherapy (CET) in methadone detoxification was studied in 28 patients. Fourteen patients received active CET; the other 14 acted as controls and received either simulated CET or only methadone detoxification therapy. One patient dropped out of the study. The Taylor Manifest Anxiety Scale and the Hamilton Anxiety Scale were administered before and after the study period. Nine of the patients receiving active CET were drug-free by the end of 8 to 10 days, and all experienced a marked reduction of their symptoms; the control group did not show significant changes. CET was clearly beneficial in the treatment of patients undergoing methadone withdrawal.

Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study

2008 ◽  
Vol 23 (2) ◽  
pp. 109-114 ◽  
Author(s):  
Nadir A. Aliyev ◽  
Zafar N. Aliyev
Keyword(s):  
Anxiety Disorder ◽  
Anxiety Disorders ◽  
Generalized Anxiety Disorder ◽  
Anxiety Scale ◽  
Generalized Anxiety ◽  
Study Group ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Hamilton Anxiety Scale ◽  
Hamilton Anxiety

AbstractObjectiveAnxiety disorders are highly prevalent in population of European countries. However, the effect of Valproate (depakine-chrono) on generalized anxiety disorder (GAD) has not been studied in a double-blind placebo-controlled design.MethodEighty patients (all men) were washout from the all medications. Each patient was randomized to receive either depakine-chrono (40 patients) for 6 weeks or matched placebo (40 patients) in a double-blind manner. Eligible participants, in addition to meeting the DSM-IV criteria for GAD and having a minimum score of 25 and more on the Hamilton Anxiety Scale, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Hamilton anxiety scale score. Response and side effects with depakine-chrono and placebo were compared by using analysis of variance (ANOVA) and chi-square tests. Six patients did not return for at least one subsequent assessment, leaving 74 patients (36 taking depakine-chrono and 38 taking placebo) in the valuables study group.ResultsTwenty six of the 36 depakine-chrono-treated participants responded by 6 weeks, versus six of the 38 placebo-treated participants (p < 0.001). The most common and problematic side effect in the depakine-chrono group was dizziness and nausea.ConclusionsThe authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of a depakine-chrono in the management of anxiety disorders. They need to be replicated in a larger study group.

Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: Systematic review and meta-analysis

2019 ◽  
Vol 33 (5) ◽  
pp. 543-547
Author(s):  
Chris Gale ◽  
Paul Glue ◽  
Giuseppe Guaiana ◽  
John Coverdale ◽  
Maeve McMurdo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Meta Analysis ◽  
Mean Difference ◽  
Anxiety Scale ◽  
Generalized Anxiety ◽  
Controlled Trials ◽  
Hamilton Anxiety Scale ◽  
Hamilton Anxiety

Background: Generalized anxiety disorder is a common psychiatric condition that is associated with decreased quality of life and significant disability. Benzodiazepines are anti-anxiety drugs used widely in the treatment of generalized anxiety disorder. This study examines the influence of several variables on benzodiazepine efficacy in generalized anxiety disorder. Method: We performed a systematic review of placebo-controlled randomized controlled trials with benzodiazepines in generalized anxiety disorder. Fifty-eight studies were deemed eligible to include in the meta-analysis. The studies dated from 1977 to 2013 and included over 5400 participants. From each paper, we extracted: benzodiazepine name and dose, dosing regimen, baseline Hamilton Anxiety Scale (HAM-A) score, change in HAM-A score at study endpoint, drop-out rate, year of study publication, diagnostic criteria used, study size, study duration, location, any conflicts of interest and side-effect profile. We then assessed the influence, direct and indirect, of individual variables on the primary outcome (mean difference at endpoint, HAM-A score). Results: Three factors were shown to be associated statistically with change in HAM-A; baseline HAM-A for benzodiazepine arm, baseline HAM-A for the placebo arm, and duration of the study. A higher baseline HAM-A in both arms was associated with a greater mean difference in HAM-A. A shorter study length was also associated with a greater mean difference. Discussion: The major factors determining benzodiazepine response was baseline anxiety level for the benzodiazepine arm and study duration. In any design of further meta-analyses and clinical trials for generalized anxiety disorder we suggest that these should be considered these as confounding factors.

The validity of the Melancholia Scale (MES) in predicting outcome of antidepressants in chronic idiopathic pain disorders

1991 ◽  
Vol 6 (3) ◽  
pp. 119-125 ◽  
Author(s):  
D Loldrup ◽  
M Langemark ◽  
HJ Hansen ◽  
M Kastrup ◽  
K Jeppesen ◽  
...  
Keyword(s):  
Construct Validity ◽  
Scale Score ◽  
Anxiety Scale ◽  
Full Recovery ◽  
Hamilton Depression Scale ◽  
Depressed Patients ◽  
Idiopathic Pain ◽  
Hamilton Anxiety Scale ◽  
Structure Evaluation ◽  
Hamilton Anxiety

SummaryIn patients with chronic idiopathic pain disorders we have analysed the construct validity of the Melancholia Scale as compared to the results with the scale in primary depression. The patients (n= 253) were treated in a placebo controlled trial with either clomipramine or mianserin independently of the Melancholia score. The construct validity of the Melancholia Scale was further analysed by the testing of the intensity model of depression versus anxiety using the Beck Depression Inventory, the Hamilton Anxiety Scale, the Spielberger State-Trait Anxiety Scale, and the Melancholia Scale. The construct validity in terms of scale homogeneity was analysed by Loevinger coefficients which can be considered as a latent structure evaluation. The Melancholia Scale showed acceptable homogeneity, while the Hamilton Anxiety Scale lacked sufficient homogeneity. In total, 33% of the patients had a score of 10 or more on the Melancholia Scale (corresponding to 13 or more on the Hamilton Depression Scale). The predictive validity of the Melancholia Scale was evaluated using active treatment versus placebo response after 6 weeks of therapy. It was shown that in patients with a Melancholia Scale score of 10 or more (corresponding to “less than major depression”) 72% had full recovery when treated with clomipramine, while 36% of the placebo treated patients obtained a full recovery (P≤0.05). The patients treated with mianserin obtained a full recovery in 52%. The group of patients with a Melancholia Scale score of 10 or more scored higher also on the anxiety scales indicating that the relation between depression and anxiety is a matter of severity. The depressed patients had significantly lower imipramine binding sites than the non-depressed patients.

A Three-Month Double-Blind Study of Clobazam versus Diazepam in Out-Patients Suffering from Neurotic Disturbances

1979 ◽  
Vol 7 (5) ◽  
pp. 404-410 ◽  
Author(s):  
H P Schjønsby ◽  
A E Gordon ◽  
D Koeppen
Keyword(s):  
Global Assessment ◽  
Anxiety Scale ◽  
Double Blind Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Significant Difference ◽  
Hamilton Anxiety Scale ◽  
Period Data ◽  
The Individual ◽  
Hamilton Anxiety

Efficacy and safety of the 1,5 benzodiazepine, clobazam, in comparison to the 1,4 benzodiazepine, diazepam, were controlled in sixty psychiatric out-patients over a period of three months. In the course of this long treatment period data were obtained confirming findings of shorter-lasting studies. Global assessment of the therapeutic efficacy and the total scores of the Hamilton Anxiety Scale revealed no significant difference between the compounds. Both groups showed a significant (p < 0.01) improvement in the total scores of the Hamilton Anxiety Scale after two weeks of treatment. Scores of the individual items indicated distinct spectra of action: Clobazam was more effective in diminishing anxious mood, whereas diazepam was better able to influence muscular symptoms of anxiety. The relevance of the findings for a more individualized therapy is pointed out.

The Hamilton Anxiety Scale

1983 ◽  
Vol 5 (2) ◽  
pp. 163-170 ◽  
Author(s):  
A. Gjerris ◽  
P. Bech ◽  
S. Bøjholm ◽  
T.G. Bolwig ◽  
P. Kramp ◽  
...  
Keyword(s):  
Anxiety Scale ◽  
Hamilton Anxiety Scale ◽  
Hamilton Anxiety

The Effect of Mental State on EPI Scores

1977 ◽  
Vol 131 (3) ◽  
pp. 306-309 ◽  
Author(s):  
G. N. Bianchi ◽  
D. M. Fergusson
Keyword(s):  
Structural Equation Model ◽  
Mental State ◽  
Structural Equation ◽  
Equation Model ◽  
Anxiety Scale ◽  
Clinical Population ◽  
Hamilton Anxiety Scale ◽  
Hamilton Anxiety

SummaryThis paper develops a structural equation model to assess the effects of mental state on EPI scores. This model is applied to results obtained from a clinical population. The findings show that: (a) the E scale is not influenced by mental state as measured by the Hamilton Anxiety Scale (HAS); (b) the N scale is influenced by HAS. An attempt to revise the N scale to produce an un-contaminated score is discussed.

The hamilton anxiety scale in patients with graves basedow disease

2011 ◽  
Vol 26 (S2) ◽  
pp. 146-146
Author(s):  
R. Danciulescu Miulescu ◽  
M.E. Calarasu ◽  
R.I. Rosca ◽  
S. Danoiu
Keyword(s):  
Psychiatric Symptoms ◽  
Significant Proportion ◽  
Specific Treatment ◽  
Anxiety Scale ◽  
Graves Disease ◽  
Altered Mental State ◽  
Hamilton Anxiety Scale ◽  
Psychiatric Manifestations ◽  
Severe Anxiety ◽  
Hamilton Anxiety

Background and aimsGraves’ disease is an autoimmune disease characterized by goitre with hyperthyroidism, Graves ophthalmopathy and pretibial myxedema The patients with Graves’ disease frequent develop a psychiatric manifestations such as mood and anxiety disorders and, cognitive dysfunction. The aims of the study is to estimate the prevalence of anxiety in patients with Graves’ disease.Materials and methods66 patients with Graves’ disease (46 women and 20 men) were recruited to this study. The subjects were between 32 and 61 years. The Hamilton Anxiety Scale (HAM-A) is a used interview scale that measures the severity of a patient’s anxiety, based on 14 items, including anxious mood, tension, fears, insomnia, somatic complaints and behaviour at the interview. The HAM-A was completed prior and after the treatment. Results were compared with measurements of HAM-A in 24 subjects without Graves’ disease.ResultsMild anxiety was present in 24 patients with Graves’ disease (36.66%-16 women and 8 men) moderate anxiety in 13 patients (19.69% - 7 women and 6 men) and severe anxiety in 3 patients (4.54%- 2 women and 1 men) prior to treatment of hyperthyroidism. After treatment of hyperthyroidism 12 patients presented mild anxiety, 6 moderate anxiety and 3 severe anxiety. The prevalence of mild anxiety was present in 2 subjects(8.33%-2 women) without Graves’ disease.ConclusionA significant proportion of patients with Graves’ disease shows an altered mental state after treatment of hyperthyroidism. When psychiatric disorders persists after restoration of euthyroidism specific treatment for the psychiatric symptoms may be needed.

Sign in / Sign up

Export Citation Format

Share Document